Emergence of Merkel Cell Carcinoma During Janus Kinase Inhibitor Therapy (ACR Convergence 2026) - Sep 8, 2026 - Abstract #738; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "A retrospective pharmacovigilance analysis was performed using FAERS reports listing tofacitinib, upadacitinib, or ruxolitinib as suspect or interacting medications. This combined case series and pharmacovigilance analysis identifies a potential association between JAK inhibitor therapy and MCC. Temporal relationships observed in several patients, together with disproportionate FAERS reporting signals, support the biological plausibility that JAK inhibition may contribute to MCC development or progression. Although causality cannot be established, clinicians should maintain awareness of this potential risk and consider individualized risk-benefit assessment and skin cancer surveillance in patients receiving JAK inhibitors."
Atopic Dermatitis • Chronic Neutrophilic Leukemia • Dermatitis • Endocrine Cancer • Genetic Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Merkel Cell Carcinoma • Myelofibrosis • Myeloproliferative Neoplasm • Non-melanoma Skin Cancer • Oncology • Polycythemia Vera • Rheumatoid Arthritis • Skin Cancer • Solid Tumor
|
|
Claire Park1; Nicole Bouché1; Victoria Wilk1; Manush Sondhi1; Peter Ch'en1; Paul Nghiem1; Namrata Singh2
|